Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

716 - HGCSG1503 : A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of cases of prior regorafenib.


24 Nov 2018


Poster display - Cocktail


Tumour Site

Colon and Rectal Cancer


Yasushi Tsuji


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


Y. Tsuji1, S. Yuki2, K. Sawada3, T. Muranaka3, Y. Kobayashi4, H. Okuda5, K. Ogawa6, S. Minami7, T. Honda8, M. Dazai9, T. Kato10, T. Sasaki11, Y. Shindo12, S. Ota13, A. Sato14, A. Ueda15, S. Saitoh16, H. Nagai17, Y. Sakata18, Y. Komatsu3

Author affiliations

  • 1 Medical Oncology, Tonan Hospital, 060-0001 - Sapporo/JP
  • 2 Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 4 Medical Oncology, Kushiro Rosai Hospital, 085-8533 - Kushiro/JP
  • 5 Medical Oncology, Keiyukai Sapporo Hospital, 003-0027 - Sapporo/JP
  • 6 Gastroenterology, Kouseiren Takaoka Hospital, Takaoka/JP
  • 7 Gastroenterology, Oji General Hospital, Tomakomai/JP
  • 8 Clinical Oncology Center, Nagaski University Hospital, 852-8501 - Nagasaki/JP
  • 9 Gastroenterology, Sapporo Medical Center NTT EC, 060-0061 - Sapporo/JP
  • 10 Internal Medicine, Wakkanai City Hospital, Wakkanai/JP
  • 11 Internal Medicine, Hokkaido Gastroenterology Hosipital, Sapporo/JP
  • 12 Gastroenterological Surgery, Nakadori General Hospital, 010-8577 - Akita/JP
  • 13 Surgery, Akita City Hospital, Akita/JP
  • 14 Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki/JP
  • 15 Medical Oncology, Toyama Red Cross Hospital, Toyama/JP
  • 16 Medical Oncology, Misawa City Hospital, Misawa/JP
  • 17 Data Center, Hokkaido Gastrointestinal Cancer Study Group, Sapporo/JP
  • 18 Ceo, Misawa City Hospital, 033-0022 - Misawa/JP


Abstract 716


The J003 trial and RECOURSE trial revealed the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer (mCRC). In March 2014, TAS-102 was approved in Japan. However, in these pivotal trials, there were few cases in which regorafenib was administered as prior treatments, and also there were few reports on the effectiveness and safety of TAS-102 after administration of regorafenib.


We retrospectively analyzed the clinical data of 411 patients who received TAS-102 in the multi-institutional retrospective study (HGCSG1503). This study was analyzed by CTCAE v4.0 for adverse events (AEs), RECIST v1.1 for response rate (RR)/disease control rate (DCR). To compare patients who received regorafenib before TAS-102 (Prior REG) and those did not receive regorafenib (No prior REG), Fisher’s exact test was used in terms of patient characteristics, AE, RR/DCR, and Log-rank test was used in terms of TTF, PFS and OS.


No prior REG and Prior REG were 285 and 126, respectively. The patient’ characteristics between No prior REG and Prior REG were generally balanced except for lung metastasis (56.8% in No prior REG, 67.5% in Prior REG; p = 0.049), prior oxaliplatin administration (95.1% in No prior REG, 99.2% in Prior REG; p = 0.045), prior irinotecan administration (90.5% in No prior REG, 100% in Prior REG; p < 0.001) and patients over 18 months since diagnosis of metastasis (63.2% in No prior REG, 84.1% in Prior REG; p < 0.001). The AEs between No prior REG and Prior REG were also generally balanced. RR/DCR were 0.8/37.5% in No prior REG and 0/36.5% in Prior REG (p = 1.000/0.908). Median PFS was 2.3 months in No prior REG and 2.1 months in Prior REG (HR 1.157, p = 0.185). Median OS was 8.1 months in No prior REG and 5.7 months in Prior REG (HR 1.355, p = 0.007).


In this analysis, No prior REG population contained lung metastasis, and short interval from diagnosis of metastasis. The adverse events, detail of administration, RR/DCR, and PFS were no significant difference regardless of the administration history of REG. The OS was significantly extended with No prior REG population. This is presumed because 30% of No prior REG population received REG for post TAS-102 therapy.

Editorial acknowledgement

Clinical trial identification

UMIN000020551, 2016/02/02.

Legal entity responsible for the study

Non-profit Organization: Hokkaido Gastrointestinal Cancer Study Group.


Non-profit Organization: Hokkaido Gastrointestinal Cancer Study Group.


S. Yuki: Honoraria: Taiho Pharmaceutical. Y. Komatsu: Honoraria, research fund, donation: Taiho Pharmaceutical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.